DADC
KITE

D.A. Davidson & Co’s Kite Pharma, Inc. KITE Stock Holding History

D.A. Davidson & Co’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,150
Closed -$119K – 2329
2017
Q2 		$119K Hold
1,150
– – ﹤0.01% 1196
2017
Q1 		$90K Sell
1,150
-200
-15% -$12.4K ﹤0.01% 1298
2016
Q4 		$60K Buy
1,350
+250
+23% +$12.3K ﹤0.01% 1530
2016
Q3 		$61K Hold
1,100
– – ﹤0.01% 1435
2016
Q2 		$55K Hold
1,100
– – ﹤0.01% 1389
2016
Q1 		$50K Hold
1,100
– – ﹤0.01% 1392
2015
Q4 		$67K Hold
1,100
– – ﹤0.01% 1286
2015
Q3 		$61K Buy
1,100
+100
+10% +$6.29K ﹤0.01% 1286
2015
Q2 		$60K Buy
+1,000
New +$57.1K ﹤0.01% 1353

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.A. Davidson & Co's KITE Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 1,150 shares — an estimated $119K sold.

D.A. Davidson & Co first reported a position in KITE in Q2 2015 and held it in 9 quarters. The position peaked at $119K in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 1,150 Kite Pharma, Inc. shares in Q3 2017, an estimated $119K.
  • D.A. Davidson & Co first reported a position in Kite Pharma, Inc. in Q2 2015 and held it in 9 quarters.
  • D.A. Davidson & Co's Kite Pharma, Inc. position peaked at $119K in Q2 2017.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.